On August 2, Gelunhui reported that Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. (hereinafter referred to as "Qingyutang"), recently received the drug supplementary application approval notice issued by the National Medical Products Administration. After review, the injection of Ceftizoxime Sodium passed the quality and efficacy consistency evaluation of generic drugs.
Ceftizoxime Sodium for injection is an anti-infective drug, mainly used to treat lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, meningitis caused by Streptococcus pneumoniae or influenza bacillus, and simple gonorrhea caused by Neisseria gonorrhoeae. According to the relevant information platform of the National Medical Products Administration, up to now, 3 enterprises (including Qingyutang) have passed the consistency evaluation or have been deemed to have passed the consistency evaluation.